To hear about similar clinical trials, please enter your email below
Trial Title:
"Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
NCT ID:
NCT05543161
Condition:
Chronic Myeloid Leukemia, Chronic Phase
Conditions: Official terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Cross-Sectional
Summary:
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm which originates from an
incomplete process of differentiation of the hematopoietic stem cells (HSCs) to the adult
cells which lead to accumulation of their immature form into the BM and the peripheral
blood. It is characterized by the reciprocal translocation. The resulting oncoprotein,
BCR/ABL1, is considered essential for the initiation and manifestation of the disease .
In CML, leukemic stem cell (LSC) supposedly resides within the CD45+/ CD34+/CD38-/Lin-
fraction of the leukemic clone (3). However, normal hematopoietic SC also exhibit this
phenotype so that additional markers are required to discriminate CML LSC from normal SC.
CD34+/CD38-/Lin- CML LSC specifically co-express dipeptidylpeptidase IV(DPPIV=CD26). This
enzyme disrupts LSC-niche interactions by degrading stroma derived factor-1 (SDF-1).
Moreover, CD26 is a robust biomarker for the quantification and isolation of CML LSC (4).
It was reported that CD26+ LSCs were significantly correlated with BCR-ABL1 transcript
level at diagnosis and after three months of treatment with tyrosine kinase inhibitor
(TKI) .
Criteria for eligibility:
Study pop:
All suspected patients for CML diagnosis aged more than 18 years who presented with high
white blood cells(WBCs) count , marked shift to left in peripheral blood with or without
splenomegaly .
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- : All suspected patients for CML diagnosis aged more than 18 years who presented
with high white blood cells(WBCs) count , marked shift to left in peripheral blood
with or without splenomegaly .
Exclusion Criteria:
- Patients on treatment or presence of blasts in peripheral blood sample.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Sohag University Hospital
Address:
City:
Sohag
Country:
Egypt
Contact:
Last name:
Magdy M Amin Amin, professor
Phone:
01002019899
Email:
portal@med.sohag.edu.eg
Start date:
October 2022
Completion date:
October 2023
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05543161
